Silent and non-silent thromboembolic events after ventricular tachycardia ablation: Modifiable risk with postprocedure anticoagulation?
Konstantinos C SiontisAmmar M KilluPublished in: Journal of cardiovascular electrophysiology (2019)
There is increasing recognition of silent and clinically apparent thromboembolic events after left-sided ventricular tachycardia (VT) ablation. However, unlike atrial fibrillation ablation procedures where postablation oral anticoagulation (OAC) is universal, there is significant practice variation in OAC use after VT ablation. Herein, we review the data on post-VT ablation thromboembolism and evidence on the use of OAC, we suggest that OAC merits consideration in most cases after a balanced assessment of risks and benefits in individual patients, and we discuss future directions.
Keyphrases
- atrial fibrillation
- catheter ablation
- left atrial
- radiofrequency ablation
- end stage renal disease
- left atrial appendage
- oral anticoagulants
- venous thromboembolism
- heart failure
- ejection fraction
- primary care
- chronic kidney disease
- direct oral anticoagulants
- healthcare
- peritoneal dialysis
- percutaneous coronary intervention
- patient reported outcomes
- acute coronary syndrome
- electronic health record
- quality improvement
- magnetic resonance imaging
- current status
- left ventricular